Recently, an open-label and single-arm clinical trial of GC027, a CD7 UCAR-T of TCR and CD7 edited by CRISPR, was published in two patients with refractory/relapsed T-ALL after potent lymphodepletion (fludarabine, cyclophosphamide, and prednisone) and a single infusion of GC027. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.